Topic: influenza

The first TV campaign for Xofluza from Roche Genentech depicts the fatigue and weakness that comes with flu.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

Roche has licensed Tamiflu to Sanofi, not in its current prescription status, but potential over-the-counter rights in the U.S.

With sales of Roche’s Tamiflu cratering, the company is anxiously monitoring successor Xofluza’s chances. New trial data provided a glimmer of hope.

Here is some other vaccine news of note for the week.

AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.

Novavax's NanoFlu vaccine beat Sanofi's Fluzone HD in seniors in a midstage test, setting up the smaller company's shot for a move into phase 3.

Here is some other vaccine news of note for the week.

After a horrible flu season last year, more people have gotten vaccinations so far this year, according to the CDC.

The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.